Cargando…
Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles
The non-canonical inflammasome sensor caspase-11 and gasdermin D (GSDMD) drive inflammation and pyroptosis, a type of immunogenic cell death that favors cell-mediated immunity (CMI) in cancer, infection, and autoimmunity. Here we show that caspase-11 and GSDMD are required for CD8(+) and Th1 respons...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873954/ https://www.ncbi.nlm.nih.gov/pubmed/36652908 http://dx.doi.org/10.1016/j.xcrm.2022.100899 |
_version_ | 1784877695551668224 |
---|---|
author | Muñoz-Wolf, Natalia Ward, Ross W. Hearnden, Claire H. Sharp, Fiona A. Geoghegan, Joan O’Grady, Katie McEntee, Craig P. Shanahan, Katharine A. Guy, Coralie Bowie, Andrew G. Campbell, Matthew Roces, Carla.B. Anderluzzi, Giulia Webb, Cameron Perrie, Yvonne Creagh, Emma Lavelle, Ed C. |
author_facet | Muñoz-Wolf, Natalia Ward, Ross W. Hearnden, Claire H. Sharp, Fiona A. Geoghegan, Joan O’Grady, Katie McEntee, Craig P. Shanahan, Katharine A. Guy, Coralie Bowie, Andrew G. Campbell, Matthew Roces, Carla.B. Anderluzzi, Giulia Webb, Cameron Perrie, Yvonne Creagh, Emma Lavelle, Ed C. |
author_sort | Muñoz-Wolf, Natalia |
collection | PubMed |
description | The non-canonical inflammasome sensor caspase-11 and gasdermin D (GSDMD) drive inflammation and pyroptosis, a type of immunogenic cell death that favors cell-mediated immunity (CMI) in cancer, infection, and autoimmunity. Here we show that caspase-11 and GSDMD are required for CD8(+) and Th1 responses induced by nanoparticulate vaccine adjuvants. We demonstrate that nanoparticle-induced reactive oxygen species (ROS) are size dependent and essential for CMI, and we identify 50- to 60-nm nanoparticles as optimal inducers of ROS, GSDMD activation, and Th1 and CD8(+) responses. We reveal a division of labor for IL-1 and IL-18, where IL-1 supports Th1 and IL-18 promotes CD8(+) responses. Exploiting size as a key attribute, we demonstrate that biodegradable poly-lactic co-glycolic acid nanoparticles are potent CMI-inducing adjuvants. Our work implicates ROS and the non-canonical inflammasome in the mode of action of polymeric nanoparticulate adjuvants and establishes adjuvant size as a key design principle for vaccines against cancer and intracellular pathogens. |
format | Online Article Text |
id | pubmed-9873954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-98739542023-01-26 Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles Muñoz-Wolf, Natalia Ward, Ross W. Hearnden, Claire H. Sharp, Fiona A. Geoghegan, Joan O’Grady, Katie McEntee, Craig P. Shanahan, Katharine A. Guy, Coralie Bowie, Andrew G. Campbell, Matthew Roces, Carla.B. Anderluzzi, Giulia Webb, Cameron Perrie, Yvonne Creagh, Emma Lavelle, Ed C. Cell Rep Med Article The non-canonical inflammasome sensor caspase-11 and gasdermin D (GSDMD) drive inflammation and pyroptosis, a type of immunogenic cell death that favors cell-mediated immunity (CMI) in cancer, infection, and autoimmunity. Here we show that caspase-11 and GSDMD are required for CD8(+) and Th1 responses induced by nanoparticulate vaccine adjuvants. We demonstrate that nanoparticle-induced reactive oxygen species (ROS) are size dependent and essential for CMI, and we identify 50- to 60-nm nanoparticles as optimal inducers of ROS, GSDMD activation, and Th1 and CD8(+) responses. We reveal a division of labor for IL-1 and IL-18, where IL-1 supports Th1 and IL-18 promotes CD8(+) responses. Exploiting size as a key attribute, we demonstrate that biodegradable poly-lactic co-glycolic acid nanoparticles are potent CMI-inducing adjuvants. Our work implicates ROS and the non-canonical inflammasome in the mode of action of polymeric nanoparticulate adjuvants and establishes adjuvant size as a key design principle for vaccines against cancer and intracellular pathogens. Elsevier 2023-01-17 /pmc/articles/PMC9873954/ /pubmed/36652908 http://dx.doi.org/10.1016/j.xcrm.2022.100899 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Muñoz-Wolf, Natalia Ward, Ross W. Hearnden, Claire H. Sharp, Fiona A. Geoghegan, Joan O’Grady, Katie McEntee, Craig P. Shanahan, Katharine A. Guy, Coralie Bowie, Andrew G. Campbell, Matthew Roces, Carla.B. Anderluzzi, Giulia Webb, Cameron Perrie, Yvonne Creagh, Emma Lavelle, Ed C. Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles |
title | Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles |
title_full | Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles |
title_fullStr | Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles |
title_full_unstemmed | Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles |
title_short | Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles |
title_sort | non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873954/ https://www.ncbi.nlm.nih.gov/pubmed/36652908 http://dx.doi.org/10.1016/j.xcrm.2022.100899 |
work_keys_str_mv | AT munozwolfnatalia noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT wardrossw noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT hearndenclaireh noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT sharpfionaa noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT geogheganjoan noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT ogradykatie noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT mcenteecraigp noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT shanahankatharinea noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT guycoralie noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT bowieandrewg noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT campbellmatthew noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT rocescarlab noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT anderluzzigiulia noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT webbcameron noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT perrieyvonne noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT creaghemma noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles AT lavelleedc noncanonicalinflammasomeactivationmediatestheadjuvanticityofnanoparticles |